Elizabeth Wulff-Burchfield, MD

Elizabeth Wulff-Burchfield, MD, University of Kansas Medical Center

Articles by Elizabeth Wulff-Burchfield, MD

Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann offer perspective on how patient-driven science is shaping QOL measurement.
View More
Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann share how they help GU patients make informed, personalized treatment decisions.
Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann discuss how GU oncologists can build trust and deepen patient connections.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.